Story thread · 2 reports / 1 sources
Repligen stock price target reaffirmed at $225 by UBS on growth outlook
investing.com · 2h
First report: UBS raises Vertex stock price target to $615 on kidney drug trial — investing.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.